Meningococcal Polysaccharide Vaccine (Groups A/C/Y and W-135)
- Atc Codes:J07AH
Table of contents
- Brand Names
- Drug Combinations
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Drug Interactions
- Dosage
Brand Names
Europe
Austria: Mencevax; Belgium: Mencevax; Finland: Mencevax; France: Mencevax; Germany: Mencevax; Hungary: Mencevax; Italy: Mencevax; UK: ACWY Vax.
North America
Canada: Menomune; USA: Menomune.
Drug combinations
Meningococcal Polysaccharide (Groups A/C/Y and W-135) Diphtheria Toxoid Conjugate Vaccine
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Vaccines. (ATC-Code: J07AH).
Mechanism of action
Induces formation of bactericidal antibodies to meningococcal antigens (immunity to meningococcal disease caused by Neisseria meningitidis groups A, C, Y and W-135).
Therapeutic use
Provides active immunity to meningococcal serogroups contained in vaccine.
Pregnancy and lactiation implications
Teratogenic effects not reported when used during pregnancy. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to any component of the formulation. Defer immunization during acute illness.
Warnings and precautions
Anaphylactoid and/or hypersensitivity reactions might occur. Asplenic patients with lymphoid tumors who receive either chemotherapy or irradiation respond poorly. Use with caution in severely immunocompromised patients (e.g. patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids). Use in pediatric patients under 2 years of age usually not recommended. Packaging may contain natural latex rubber. Some dosage forms contain thimerosal.